QTA in pharma commonly stands for Quality Technical Agreement, also called a pharmaceutical quality agreement. In contract drug manufacturing, it should assign who performs, reviews, approves, notifies and retains evidence for every critical activity. It should cover document and change control, deviations and OOS, complaints and recalls, audits, validation, data integrity, materials, release interfaces, subcontracting, regulatory communication and records. Commercial terms belong in the commercial agreement, but the two agreements must not conflict. Responsibility cannot be outsourced; scope, market and governing requirements determine the final matrix.
A useful quality agreement is not a ceremonial appendix to a supply contract. It is the operating map for how the product owner, authorization holder, contract giver, contract acceptor, testing laboratory and other responsible parties will keep a medicine and its evidence under control.
1. Begin with the principle that responsibility is not outsourced
FDA's quality-agreement guidance states that parties in contract drug manufacturing can use written quality agreements to define and document manufacturing activities and CGMP responsibilities. It also makes clear that such an agreement does not relieve either party of its applicable responsibilities. EU GMP Chapter 7 similarly expects outsourced activities to be correctly defined, agreed and controlled. [1] [2]
China's Drug Administration Law requires the marketing authorization holder to audit the quality management system of a contracted manufacturer and to sign agreements covering delegated manufacture and quality. The current NMPA contract-manufacturing announcement further requires both parties to fulfil their contract and quality-agreement obligations. [3] [4]
The practical rule is simple: the agreement may allocate activities, but it cannot make a responsible organization stop exercising oversight.
1A. For marketed drugs in China, test four practical gates before signature
NMPA's current contract-manufacturing announcement makes the preliminary screen more than a commercial formality. Before accepting a marketed-drug project, the proposed contract manufacturer is expected to evaluate the MAH, the product risk, technical-transfer feasibility and co-line feasibility; the agreements follow a passed evaluation. [3]
- Fit before commitment: document the legal entity, product route, quality-management capability, transfer readiness and shared-line risk that were assessed.
- Access and interface: specify the MAH's right to consult relevant systems, procedures, documents and records, inspect relevant sites, and identify the named quality-system interfaces.
- Risk communication: define the people, channels and timeframes for at least deviations, changes, OOS/OOT results, qualification and validation, retention samples and stability, pharmacovigilance, inspection status and relevant credit or compliance information.
- Sterile-product governance: where the notice applies, treat sterile manufacture as a higher-risk route requiring explicit validation oversight and access arrangements—not as a generic claim about every project or market.
These are China-specific regulatory expectations for the scope addressed by the NMPA notice. They do not replace the legal, MAH, import-market or product-specific requirements that apply to an individual project.
1B. Use a current local regulatory checklist to make the agreement auditable
2. Define five verbs for every critical activity
For each activity, the agreement should answer five questions: who performs it, who reviews the evidence, who approves the decision, who must be notified, and who retains the authoritative record. A RACI-style matrix can help, but narrative detail is still needed where timing, escalation or market-specific duties matter.
3. Cover the complete responsibility matrix
| Domain | What the agreement should define |
|---|---|
| Governance | Named quality contacts, decision authority, meeting rhythm, escalation route, emergency availability and controlled language. |
| Product and process | Ownership and approval of specifications, master documents, control strategy, manufacturing instructions and technical knowledge. |
| Materials and suppliers | Supplier qualification, approved sources, sampling, testing, status control, release and change notification. |
| Facilities and validation | Qualification, cleaning, process validation, computerized systems, utilities, maintenance and continued verification. |
| Records and data | Original records, metadata, audit trails, access, review, retention, copies, translations, backups and data-integrity investigations. |
| Batch disposition | Manufacture, testing, record review, certification or release support, rejection, rework and destruction. |
| Events and CAPA | Deviation, OOS/OOT, atypical results, investigation leadership, root cause, impact assessment, CAPA approval and effectiveness checks. |
| Change control | Which changes require prior approval, regulatory impact assessment, validation, market notification and inventory transition. |
| Stability and samples | Protocol, storage, testing, trending, reference/retention samples, alert handling and shelf-life decisions. |
| Complaints and recalls | Intake, investigation, medical or quality assessment, health-authority reporting, recall decisions, execution and effectiveness. |
| Audits and inspections | Audit rights, frequency, access to records, response timelines, regulatory inspection notification and observation management. |
| Subcontracting | Activities that may be further outsourced, prior approval, qualification and flow-down of quality obligations. |
| Continuity and termination | Shortage escalation, disaster recovery, data access, transfer assistance, inventory and record custody after termination. |
Sterile products: assign the control and evidence interfaces
For a sterile-product route, a quality agreement should do more than say both parties “follow GMP.” Map who performs, reviews, approves, notifies and retains evidence for the controls that apply to the named product and market. EU GMP Annex 1 describes sterile-manufacturing controls; the FDA quality-agreement guidance [1] and EU GMP Chapter 7 [2] address responsibilities in outsourced work. These references do not prescribe one universal agreement template or establish that a particular facility is compliant.
- Contamination control: identify the owner of the contamination control strategy (CCS), linked facility and equipment controls, change reviews and access to relevant records.
- Route-specific validation: distinguish aseptic-process simulation and intervention evidence from terminal-sterilization validation, as applicable; assign review and escalation for adverse results.
- Monitoring and investigations: define who trends environmental, process and microbiological data; investigates excursions or out-of-specification results; notifies the other party; and approves corrective actions.
- Closure and disposition: allocate container-closure integrity evidence where relevant, batch-record review, release-support activities and final legal disposition under the target market's rules.
Use the sterile contract-manufacturer evaluation guide to frame evidence questions, then record the agreed interfaces in the controlled responsibility matrix. Product, site, parties and jurisdiction must be checked case by case; this section is not a conclusion about Hainan Hailing's project fit, capacity or regulatory status.
EU/EEA projects: four sample-custody questions
For a relevant European Union / European Economic Area (EU/EEA) product route, make sample custody explicit in the quality agreement. The revised Annex 19 applies from 24 September 2026; its stated revision focus is parallel-traded products. The core interfaces below were already present in the previous version (§§2, 6–8 and 10), not four newly created obligations.
- Which sample serves which purpose? Distinguish reference samples for possible analysis from fully packaged retention samples for identification.
- Where is each category taken and held? Record locations and responsible parties in written agreements. For non-EEA manufacture without an operational mutual recognition agreement (MRA), finished-product reference samples belong at an authorised EEA manufacturer; an operational MRA may permit original-site storage. Retention samples remain at an authorised EEA manufacturer, preferably the certifying Qualified Person (QP)'s site.
- How are samples retrieved? Agree QP access at reasonable times, ready availability of reference samples to a laboratory with validated methods, and traceability records available for authority review.
- What happens on manufacturer closedown? Where the manufacturing authorisation is surrendered, revoked or ceases, arrange transfer of samples and relevant GMP records to authorised storage, continued access/analysis and authority consultation. Identify the marketing authorisation holder (MAH)'s delegation duties and the importer's particular responsibility for non-EEA closedown (§10).
Sources: 2026 Annex 19, C(2026) 4135 final, 23 June 2026; previous Annex 19, issued 14 December 2005, operational 1 June 2006; Commission announcement, 24 June 2026 / applicable 24 September 2026. These sources were checked for this subsection on 6 October 2026.
These are editorial diligence questions, not an official questionnaire, signed agreement or proof of Hailing's EU qualification. Check the named product, parties, site and market. Contract termination alone is not the §10 closedown scenario. Existing downloadable worksheets have not been revised by this addition.
4. Separate quality terms from commercial terms—but reconcile them
Price, payment, liability caps, exclusivity and commercial forecasts normally belong in the commercial agreement. Quality decisions, evidence, approval rights and notification timelines belong in the quality agreement. The two documents must not contradict each other. For example, a shipping target cannot override batch disposition, and termination language cannot remove access to required records or investigation support.
5. Set measurable notification and decision timelines
Words such as “promptly” or “as appropriate” are often too vague for critical events. Define timeframes for serious deviations, potential product defects, data-integrity concerns, regulatory contact, supply interruption and proposed changes. State which clock applies, who can extend it and how unresolved issues escalate.
6. Test the agreement with scenarios before go-live
Run short tabletop exercises: an OOS result appears before a planned shipment; a primary-packaging supplier changes a site; a data system becomes unavailable; a complaint suggests a serious quality defect; an inspector requests records held by the other party. If the team cannot identify the decision owner, evidence route and notification deadline, the agreement is not yet operational.
7. Review it across the product lifecycle
ICH Q10 treats outsourced activities as part of the pharmaceutical quality system. The agreement should therefore be reviewed at planned intervals and after material changes: new market, new dosage form or strength, site or equipment change, ownership change, recurring deviation, inspection outcome, new subcontractor, regulatory variation or transfer of authorization. [5]
Frequently asked questions
What is the full form and meaning of QTA in pharma?
In pharma, QTA commonly stands for Quality Technical Agreement, often called a pharmaceutical quality agreement. It is the written operating framework that assigns quality-critical responsibilities between parties. It should identify who performs, reviews, approves, communicates and retains evidence; it does not transfer statutory responsibility or replace a commercial agreement.
Is a quality agreement the same as a commercial manufacturing agreement?
No. They should be coordinated, but the quality agreement focuses on quality-critical activities, evidence, decisions and communication.
Can the contract manufacturer release the product?
The answer depends on the role, market and applicable law. The agreement should distinguish site testing and batch-disposition activities from the final legal release or certification responsibility.
Should every SOP be copied into the agreement?
No. The agreement should identify governing systems, interfaces and approval rights. Detailed methods can remain in controlled procedures referenced by the agreement.
When should the quality agreement be signed?
Early enough to influence technical transfer, validation, data exchange and regulatory planning—before quality-critical execution begins.
How often should it be reviewed?
Use a defined periodic review and event-driven review after material changes, significant events or new regulatory obligations.
Authoritative sources
- U.S. FDA — Contract Manufacturing Arrangements for Drugs: Quality Agreements
- European Commission — EU GMP Chapter 7: Outsourced Activities
- NMPA — Announcement on Strengthening Supervision and Administration of Contract Manufacturing of Drugs (No. 134, 2025)
- NMPA — Drug Administration Law of the People's Republic of China
- ICH Q10 — Pharmaceutical Quality System
- Hainan Medical Products Administration — Measures on MAH responsibility and full-chain quality supervision for contract manufacturing (2026)
- European Commission — EU GMP Annex 1: Manufacture of Sterile Medicinal Products
This article is an industry perspective for general business discussion. It is not legal, regulatory or medical advice. Project requirements must be confirmed with the responsible parties and applicable authorities.